AMPIO PHARMACEUTICALS, INC.: 10-K filed 2016-02-26

Name: AMPIO PHARMACEUTICALS, INC.: 10-K filed 2016-02-26
Creator: AMPIO PHARMACEUTICALS, INC.
License: https://creativecommons.org/licenses/by/4.0/

What AMPIO PHARMACEUTICALS, INC. reported in its annual report filed 2016-02-26 (fiscal FY 2015): 31 published measures, 124 facts as tagged in accession 0001193125-16-479780.

This filing

Form: 10-K (annual report)
Filed: 2016-02-26
Fiscal period: fiscal FY 2015
Accession: 0001193125-16-479780 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All AMPIO PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2015-12-31	50,418,593	USD
At 2014-12-31	70,268,410	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2015-12-31	12,491,605	USD
At 2014-12-31	4,809,892	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2015-12-31	36,999,158	USD
At 2014-12-31	66,118,265	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2015-12-31	26,957,938	USD
At 2014-12-31	50,320,656	USD
At 2013-12-31	26,309,449	USD
At 2012-12-31	17,682,517	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2015-10-01 to 2015-12-31	-10,005,693	USD	92
2015-01-01 to 2015-12-31	-32,010,242	USD	365
2015-07-01 to 2015-09-30	-7,365,540	USD	92
2015-04-01 to 2015-06-30	-7,355,426	USD	91
2015-01-01 to 2015-03-31	-7,283,583	USD	90
2014-10-01 to 2014-12-31	-9,911,682	USD	92
2014-01-01 to 2014-12-31	-38,125,415	USD	365
2014-07-01 to 2014-09-30	-9,280,030	USD	92
2014-04-01 to 2014-06-30	-8,691,520	USD	91
2014-01-01 to 2014-03-31	-10,242,183	USD	90
2013-01-01 to 2013-12-31	-24,008,558	USD	365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2015-01-01 to 2015-12-31	235,656	USD	365
2014-01-01 to 2014-12-31	8,668,351	USD	365
2013-01-01 to 2013-12-31	1,311,383	USD	365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2015-10-01 to 2015-12-31	469,213	USD	92
2015-01-01 to 2015-12-31	1,162,462	USD	365
2015-07-01 to 2015-09-30	487,385	USD	92
2015-04-01 to 2015-06-30	184,435	USD	91
2015-01-01 to 2015-03-31	21,429	USD	90
2014-10-01 to 2014-12-31	21,429	USD	92
2014-01-01 to 2014-12-31	76,787	USD	365
2014-07-01 to 2014-09-30	21,429	USD	92
2014-04-01 to 2014-06-30	21,429	USD	91
2014-01-01 to 2014-03-31	12,500	USD	90
2013-01-01 to 2013-12-31	50,000	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2015-12-31	-133,914,812	USD
At 2014-12-31	-101,904,570	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Unit	Days
2015-01-01 to 2015-12-31	USD	365
2014-01-01 to 2014-12-31	USD	365
2013-01-01 to 2013-12-31	USD	365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2015-12-31	9,331,446	USD
At 2014-12-31	9,945,428	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2015-01-01 to 2015-12-31	6,171,127	USD	365
2014-01-01 to 2014-12-31	7,852,666	USD	365
2013-01-01 to 2013-12-31	3,448,285	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2015-01-01 to 2015-12-31	-33,302,119	USD	365
2014-01-01 to 2014-12-31	-39,071,035	USD	365
2013-01-01 to 2013-12-31	-24,023,873	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2015-12-31	29,228,422	USD
At 2014-12-31	51,259,157	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2015-12-31	5,515,113	USD
At 2014-12-31	3,679,983	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2015-12-31	2,880,662	USD
At 2014-12-31	3,299,025	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit	Days
At 2015-12-31	221,000	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2015-12-31	593,382	USD
At 2014-12-31	664,169	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2015-10-01 to 2015-12-31	10,777,271	USD	92
2015-01-01 to 2015-12-31	34,464,581	USD	365
2015-07-01 to 2015-09-30	8,159,595	USD	92
2015-04-01 to 2015-06-30	7,906,441	USD	91
2015-01-01 to 2015-03-31	7,621,274	USD	90
2014-10-01 to 2014-12-31	10,179,794	USD	92
2014-01-01 to 2014-12-31	39,147,822	USD	365
2014-07-01 to 2014-09-30	9,518,641	USD	92
2014-04-01 to 2014-06-30	8,961,630	USD	91
2014-01-01 to 2014-03-31	10,487,757	USD	90
2013-01-01 to 2013-12-31	24,073,873	USD	365

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2015-10-01 to 2015-12-31	4,755,554	USD	92
2015-01-01 to 2015-12-31	15,134,727	USD	365
2015-07-01 to 2015-09-30	3,410,920	USD	92
2015-04-01 to 2015-06-30	4,007,195	USD	91
2015-01-01 to 2015-03-31	2,961,058	USD	90
2014-10-01 to 2014-12-31	2,939,395	USD	92
2014-01-01 to 2014-12-31	12,224,834	USD	365
2014-07-01 to 2014-09-30	3,322,544	USD	92
2014-04-01 to 2014-06-30	3,304,123	USD	91
2014-01-01 to 2014-03-31	2,658,772	USD	90
2013-01-01 to 2013-12-31	7,477,396	USD	365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2015-01-01 to 2015-12-31	18,960,545	USD	365
2014-01-01 to 2014-12-31	26,923,000	USD	365
2013-01-01 to 2013-12-31	16,596,000	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2015-12-31	51,998,306	shares
At 2014-12-31	51,972,266	shares

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit
At 2015-12-31	37,926,988	USD
At 2014-12-31	65,458,518	USD
At 2013-12-31	33,214,870	USD
At 2012-12-31	23,830,022	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2015-12-31	1,277,000	USD
At 2014-12-31	419,000	USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

Period	Value	Unit	Days
At 2015-12-31	2,909,583	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2015-10-01 to 2015-12-31	-10,622,184	USD	92
2015-01-01 to 2015-12-31	-33,713,917	USD	365
2015-07-01 to 2015-09-30	-7,786,635	USD	92
2015-04-01 to 2015-06-30	-7,713,678	USD	91
2015-01-01 to 2015-03-31	-7,591,420	USD	90
2014-10-01 to 2014-12-31	-10,152,649	USD	92
2014-01-01 to 2014-12-31	-39,048,772	USD	365
2014-07-01 to 2014-09-30	-9,491,665	USD	92
2014-04-01 to 2014-06-30	-8,932,696	USD	91
2014-01-01 to 2014-03-31	-10,471,762	USD	90
2013-01-01 to 2013-12-31	-24,528,426	USD	365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2015-01-01 to 2015-12-31	858,000	USD	365
2014-01-01 to 2014-12-31	368,000	USD	365
2013-01-01 to 2013-12-31	72,000	USD	365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2015-01-01 to 2015-12-31	71,000	USD	365
2014-01-01 to 2014-12-31	71,000	USD	365
2013-01-01 to 2013-12-31	66,000	USD	365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2015-10-01 to 2015-12-31	-314,126	USD	92
2015-07-01 to 2015-09-30	-114,425	USD	92
2015-04-01 to 2015-06-30	8,328	USD	91
2015-01-01 to 2015-03-31	8,425	USD	90
2014-10-01 to 2014-12-31	5,716	USD	92
2014-07-01 to 2014-09-30	5,547	USD	92
2014-04-01 to 2014-06-30	7,505	USD	91
2014-01-01 to 2014-03-31	3,495	USD	90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2015-01-01 to 2015-12-31	-411,798	USD	365
2014-01-01 to 2014-12-31	22,263	USD	365
2013-01-01 to 2013-12-31	-504,553	USD	365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2014-01-01 to 2014-12-31	68,394,051	USD	365
2013-01-01 to 2013-12-31	25,301,735	USD	365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2015-01-01 to 2015-12-31	-426,071	USD	365
2014-01-01 to 2014-12-31	1,020,496	USD	365
2013-01-01 to 2013-12-31	699,454	USD	365

Inspect the source

Entity: AMPIO PHARMACEUTICALS, INC. / CIK 0001411906
Captured: 2026-09-22 19:47 UTC
SEC response SHA-256: 661bdc81760eff21f73144c4212b3daf37fe49f00b5469e6e153f0c2138a63e3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001411906.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))